News | November 27, 2025
Investors pile in as Cordance secures oversubscribed seed round for brain-cancer tech
The fresh capital will propel Cordance into its first-in-human clinical trial
The fresh capital will propel Cordance into its first-in-human clinical trial
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis
The Eurasian Patent Organization (EAPO) has granted Patent, protecting the company’s sublingual delivery technology for anticancer drugs used to treat autoimmune and neurodegenerative diseases
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
Winlevi is authorized in EU for the treatment of acne vulgaris
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The 2025 edition of the EdelGive Hurun list recognizes 24 exceptional women leaders for their philanthropic impact across critical areas
The initiative aims to connect startups and tech companies with its business units,
Subscribe To Our Newsletter & Stay Updated
